Inflammation — Association of MLR With Risk of Death and Cardiovascular Events in PD Patients
Citation(s)
Afari ME, Bhat T Neutrophil to lymphocyte ratio (NLR) and cardiovascular diseases: an update. Expert Rev Cardiovasc Ther. 2016;14(5):573-7. doi: 10.1586/14779072.2016.1154788. Epub 2016 Mar 4. Review.
Agarwal R, Light RP Patterns and prognostic value of total and differential leukocyte count in chronic kidney disease. Clin J Am Soc Nephrol. 2011 Jun;6(6):1393-9. doi: 10.2215/CJN.10521110. Epub 2011 May 5.
Akchurin OM, Kaskel F Update on inflammation in chronic kidney disease. Blood Purif. 2015;39(1-3):84-92. doi: 10.1159/000368940. Epub 2015 Jan 20. Review.
Betjes MG Immune cell dysfunction and inflammation in end-stage renal disease. Nat Rev Nephrol. 2013 May;9(5):255-65. doi: 10.1038/nrneph.2013.44. Epub 2013 Mar 19. Review.
Carrero JJ, Stenvinkel P Inflammation in end-stage renal disease--what have we learned in 10 years? Semin Dial. 2010 Sep-Oct;23(5):498-509. doi: 10.1111/j.1525-139X.2010.00784.x. Review.
Cho Y, Hawley CM, Johnson DW Clinical causes of inflammation in peritoneal dialysis patients. Int J Nephrol. 2014;2014:909373. doi: 10.1155/2014/909373. Epub 2014 May 6. Review.
Ernandez T, Mayadas TN The Changing Landscape of Renal Inflammation. Trends Mol Med. 2016 Feb;22(2):151-163. doi: 10.1016/j.molmed.2015.12.002. Epub 2016 Jan 7. Review.
Hou H, Sun T, Li C, Li Y, Guo Z, Wang W, Li D An overall and dose-response meta-analysis of red blood cell distribution width and CVD outcomes. Sci Rep. 2017 Feb 24;7:43420. doi: 10.1038/srep43420.
Jegatheesan D, Cho Y, Johnson DW Clinical Studies of Interventions to Mitigate Cardiovascular Risk in Peritoneal Dialysis Patients. Semin Nephrol. 2018 May;38(3):277-290. doi: 10.1016/j.semnephrol.2018.02.007. Review.
Kim JH, Lim S, Park KS, Jang HC, Choi SH Total and differential WBC counts are related with coronary artery atherosclerosis and increase the risk for cardiovascular disease in Koreans. PLoS One. 2017 Jul 28;12(7):e0180332. doi: 10.1371/journal.pone.0180332. eCollection 2017.
Lameire N, Van Biesen W Epidemiology of peritoneal dialysis: a story of believers and nonbelievers. Nat Rev Nephrol. 2010 Feb;6(2):75-82. doi: 10.1038/nrneph.2009.210. Epub 2009 Dec 15. Review.
Laudanski K, Nowak Z Aberrant function and differentiation of monocytes in end stage renal disease. Arch Immunol Ther Exp (Warsz). 2012 Dec;60(6):453-9. doi: 10.1007/s00005-012-0191-0. Epub 2012 Oct 19. Review.
Li H, Lu X, Xiong R, Wang S High Neutrophil-to-Lymphocyte Ratio Predicts Cardiovascular Mortality in Chronic Hemodialysis Patients. Mediators Inflamm. 2017;2017:9327136. doi: 10.1155/2017/9327136. Epub 2017 Feb 21.
Li PK, Ng JK, Mcintyre CW Inflammation and Peritoneal Dialysis. Semin Nephrol. 2017 Jan;37(1):54-65. doi: 10.1016/j.semnephrol.2016.10.007. Review.
Liakopoulos V, Roumeliotis S, Gorny X, Eleftheriadis T, Mertens PR Oxidative Stress in Patients Undergoing Peritoneal Dialysis: A Current Review of the Literature. Oxid Med Cell Longev. 2017 Dec 27;2017:3494867. doi: 10.1155/2017/3494867. eCollection 2017. Review.
Miller LM, Sood MM, Sood AR, Reslerova M, Komenda P, Rigatto C, Bueti J Cardiovascular disease in end-stage renal disease: the challenge of assessing and managing cardiac disease in dialysis patients. Int Urol Nephrol. 2010 Dec;42(4):1007-14. doi: 10.1007/s11255-010-9857-x. Epub 2010 Oct 20. Review.
Miyamoto T, Carrero JJ, Stenvinkel P Inflammation as a risk factor and target for therapy in chronic kidney disease. Curr Opin Nephrol Hypertens. 2011 Nov;20(6):662-8. doi: 10.1097/MNH.0b013e32834ad504. Review.
Ommen SR, Gibbons RJ, Hodge DO, Thomson SP Usefulness of the lymphocyte concentration as a prognostic marker in coronary artery disease. Am J Cardiol. 1997 Mar 15;79(6):812-4.
Saionji K, Ohsaka A Expansion of CD4+CD16+ blood monocytes in patients with chronic renal failure undergoing dialysis: possible involvement of macrophage colony-stimulating factor. Acta Haematol. 2001;105(1):21-6.
Saran R, Steffick D, Bragg-Gresham J The China Kidney Disease Network (CK-NET): "Big Data-Big Dreams". Am J Kidney Dis. 2017 Jun;69(6):713-716. doi: 10.1053/j.ajkd.2017.04.008. Review.
Saxena AB Recent advances in the management of peritoneal dialysis patients. F1000Prime Rep. 2015 May 1;7:57. doi: 10.12703/P7-57. eCollection 2015. Review.
Taymez DG, Ucar E, Turkmen K, Ucar R, Afsar B, Gaipov A, Turk S The Predictive Value of Platelet/Lymphocyte Ratio in Hemodialysis Patients With Erythropoietin Resistance. Ther Apher Dial. 2016 Apr;20(2):118-21. doi: 10.1111/1744-9987.12380. Epub 2016 Mar 1.
Turkmen K, Guney I, Yerlikaya FH, Tonbul HZ The relationship between neutrophil-to-lymphocyte ratio and inflammation in end-stage renal disease patients. Ren Fail. 2012;34(2):155-9. doi: 10.3109/0886022X.2011.641514. Epub 2011 Dec 16.
Xiang F, Chen R, Cao X, Shen B, Liu Z, Tan X, Ding X, Zou J Monocyte/lymphocyte ratio as a better predictor of cardiovascular and all-cause mortality in hemodialysis patients: A prospective cohort study. Hemodial Int. 2018 Jan;22(1):82-92. doi: 10.1111/hdi.12549. Epub 2017 Apr 12.
Zouridakis EG, Garcia-Moll X, Kaski JC Usefulness of the blood lymphocyte count in predicting recurrent instability and death in patients with unstable angina pectoris. Am J Cardiol. 2000 Aug 15;86(4):449-51.
Association of Monocyte / Lymphocyte Ratio With Risk of Death and Cardiovascular Events in Peritoneal Dialysis Patients
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.